NervGen Pharma Corp. (NGEN.V)
| Previous Close | 1.8500 |
| Open | 1.8000 |
| Bid | 1.6900 x 0 |
| Ask | 1.7100 x 0 |
| Day's Range | 1.6800 - 1.8000 |
| 52 Week Range | 1.5200 - 3.3300 |
| Volume | |
| Avg. Volume | 38,108 |
| Market Cap | 99.526M |
| Beta (5Y Monthly) | 1.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3680 |
| Earnings Date | Nov 16, 2022 - Nov 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.25 |
- Newsfile
NervGen Pharma Announces Leadership Transition
Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer Dr. Adam Rogers, member of the Board of Directors, appointed interim President Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors; will serve as a strategic advisor for a transition periodVancouver, British Columbia--(Newsfile Corp. - September 22, 2022) - NervGen Pharma Corp. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company ...
- Newsfile
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
Expands research capabilities aiming to build pipeline of proprietary compounds for nervous system repairDr. Lukashev brings over 20 years' experience including work at Biogen and the ALS Therapy Development Institute Vancouver, British Columbia--(Newsfile Corp. - September 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased t
- News Direct
Has The Controversy Around Falsified Alzheimer's Research Impacted The Path To Finding The Cure?
By Paul Henley, Benzinga
